menu
    • menu
    [{"orgOrder":0,"company":"ArQule","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"ARQ 531","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"ArQule","amount2":2.7000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":2.7000000000000002,"dosageForm":"Oral","sponsorNew":"ArQule \/ Merck","highestDevelopmentStatusID":"8","companyTruncated":"ArQule \/ Merck"}]

    Find Clinical Drug Pipeline Developments & Deals for ARQ 531

    Menu

    ARQ 531

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ArQule

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            ArQule

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ARQ 531

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Merck & Co

                            Deal Size : $2,700.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Merck Completes Acquisition of ArQule

                            Details : ArQule became a wholly owned subsidiary of Merck upon completion of the acquisition.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 17, 2020

                            Lead Product(s) : ARQ 531

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Merck & Co

                            Deal Size : $2,700.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth